177 related articles for article (PubMed ID: 20656694)
1. Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Shukuya T; Yasui H; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2010 Dec; 40(12):1135-8. PubMed ID: 20656694
[TBL] [Abstract][Full Text] [Related]
2. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Takahara N; Isayama H; Nakai Y; Ishigami H; Satoi S; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Yamaguchi H; Tada M; Kitayama J; Watanabe T; Koike K
Invest New Drugs; 2016 Oct; 34(5):636-42. PubMed ID: 27339809
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
Maeda S; Motoi F; Onogawa T; Morikawa T; Shigeru O; Sakata N; Takadate T; Naitoh T; Rikiyama T; Katayose Y; Egawa S; Unno M
Int J Clin Oncol; 2011 Oct; 16(5):539-45. PubMed ID: 21455624
[TBL] [Abstract][Full Text] [Related]
5. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
8. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigami H; Yamashita H; Yamaguchi H; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Mohri D; Kawakubo K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Kitayama J; Watanabe T; Koike K
J Gastrointest Cancer; 2014 Sep; 45(3):307-11. PubMed ID: 24676891
[TBL] [Abstract][Full Text] [Related]
9. Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre.
Ostwal V; Sahu A; Zanwar S; Nayak L; Shrikhande SV; Shetty N; Gupta S; Ramaswamy A
Indian J Med Res; 2018 Sep; 148(3):284-290. PubMed ID: 30425218
[TBL] [Abstract][Full Text] [Related]
10. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Park JH; Lee JL
Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
[TBL] [Abstract][Full Text] [Related]
11. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
John P; Butler H; Saif MW
Anticancer Res; 2014 Dec; 34(12):7267-70. PubMed ID: 25503159
[TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
13. Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Wang F; Du X; Li X; Liu N; Yu H; Sheng X
Medicine (Baltimore); 2016 Dec; 95(51):e5696. PubMed ID: 28002342
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Hayuka K; Okuyama H; Murakami A; Okita Y; Nishiuchi T; Okano K; Suzuki Y; Tsuji A
Chemotherapy; 2021; 66(3):58-64. PubMed ID: 34284397
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
17. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
18. Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients.
Rau KM; Li SH; Chen SM; Tang Y; Huang CH; Wu SC; Chen YY
Jpn J Clin Oncol; 2011 Apr; 41(4):455-61. PubMed ID: 21193489
[TBL] [Abstract][Full Text] [Related]
19. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.
Kokkali S; Tripodaki ES; Drizou M; Stefanou D; Magou E; Zylis D; Kapiris M; Nasi D; Georganta C; Ardavanis A
In Vivo; 2018; 32(3):653-657. PubMed ID: 29695574
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
